Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
2 citing papers in PubMed, 3 citations in OpenAlex.
Prostaglandin ICellular and molecular life sciences : CMLS · 2024
Article
4 · The record
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
12 authors at 6 institutions in 1 country.
Jelena KornejNational Heart, Lung, and Blood Institute, Boston University's Framingham Heart Study, Framingham, MA, USA. jkornej@bu.edu.ORCID 0000-0003-3551-1145
Maha A QadanDepartment of Cardiovascular and Metabolic Sciences, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, OH, USA.ORCID 0000-0002-7478-5723
Mona AlotaibiDivision of Pulmonary, Critical Care and Sleep Medicine, University of California San Diego, La Jolla, CA, USA.ORCID 0000-0001-8492-9930
David R Van WagonerDepartment of Cardiovascular and Metabolic Sciences, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, OH, USA.ORCID 0000-0001-8250-9828
Jeramie D WatrousDepartment of Medicine, University of California, La Jolla, San Diego, CA, USA.
Ludovic TrinquartNational Heart, Lung, and Blood Institute, Boston University's Framingham Heart Study, Framingham, MA, USA.ORCID 0000-0002-3028-4900
Sarah R PreisNational Heart, Lung, and Blood Institute, Boston University's Framingham Heart Study, Framingham, MA, USA.ORCID 0000-0002-9360-4166
Darae KoNational Heart, Lung, and Blood Institute, Boston University's Framingham Heart Study, Framingham, MA, USA.ORCID 0000-0002-1174-7535
Mohit JainDepartment of Medicine, University of California, La Jolla, San Diego, CA, USA.ORCID 0000-0001-8628-2069
Emelia J BenjaminNational Heart, Lung, and Blood Institute, Boston University's Framingham Heart Study, Framingham, MA, USA.ORCID 0000-0003-4076-2336
Susan Cheng *Department of Cardiology, Cedars-Sinai Medical Center, Smidt Heart Institute, Los Angeles, CA, USA.
Honghuang Lin *National Heart, Lung, and Blood Institute, Boston University's Framingham Heart Study, Framingham, MA, USA.ORCID 0000-0003-3043-3942
Boston University · USCleveland Clinic · USUniversity of California San Diego · USCedars-Sinai Medical Center · USUniversity of California System · USUniversity of Massachusetts Chan Medical School · US
Funding
IDENTIFICATION OF COMMON GENETIC VARIANTS FOR ATRIAL FIBRILLATION AND PR INTERVALR01HL092577 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI BENJAMIN, EMELIA J., ELLINOR, PATRICK THOMAS · 2009 to 2025
$20.6M
The Microvascular Aging and Eicosanoids - Women's Evaluation of Systemic Aging Tenacity (MAE-WEST) ("You are never too old to become younger!") Specialized Center for Research Excellence (SCORE)U54AG065141 · NIA · CEDARS-SINAI MEDICAL CENTER · PI BAIREY MERZ, CATHLEEN NOEL · 2020 to 2024
$8.7M
Cardiac microstructure and the immune-inflammatory response to SARS-CoV-2R01HL131532 · NHLBI · CEDARS-SINAI MEDICAL CENTER · PI CHENG, SUSAN, LI, DEBIAO · 2016 to 2025
$6.6M
Functional Genomics of Atrial Fibrillation in Human AtriaR01HL111314 · NHLBI · CLEVELAND CLINIC LERNER COM-CWRU · PI BARNARD, JOHN, CHUNG, MINA KAY · 2012 to 2019
$6.1M
Mediators of Systemic Inflammation and Heart Failure Risk in the CommunityR01HL143227 · NHLBI · CEDARS-SINAI MEDICAL CENTER · PI CHENG, SUSAN · 2019 to 2022
$3.3M
CAPSITE: Community Assessment of Pain and Sensitization in the ElderlyR01AG066010 · NIA · BOSTON UNIVERSITY MEDICAL CAMPUS · PI BENJAMIN, EMELIA J., EDWARDS, ROBERT R · 2020 to 2025
$3.3M
Vaccine Induced Immune-Inflammatory Response and Cardiovascular RiskR01HL151828 · NHLBI · CEDARS-SINAI MEDICAL CENTER · PI CHENG, SUSAN · 2021 to 2024
$3.0M
Assessing Alzheimer disease risk and heterogeneity using multimodal machine learning approachesU01AG068221 · NIA · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI DESTEFANO, ANITA L, LIN, HONGHUANG · 2021 to 2024
$2.5M
Aging and Inflammation: Longitudinal Markers and Genetics in the Framingham StudyR01AG028321 · NIA · BOSTON UNIVERSITY MEDICAL CAMPUS · PI BENJAMIN, EMELIA J. · 2006 to 2010
Chronic inflammation is a continuous low-grade activation of the systemic immune response. Whereas downstream inflammatory markers are associated with atrial fibrillation (AF), upstream inflammatory effectors including eicosanoids are less studied. To examine the association between eicosanoids and incident AF. We used a liquid chromatography-mass spectrometry for the non-targeted measurement of 161 eicosanoids and eicosanoid-related metabolites in the Framingham Heart Study. The association of each eicosanoid and incident AF was assessed using Cox proportional hazards models and adjusted for AF risk factors, including age, sex, height, weight, systolic/diastolic blood pressure, current smoking, antihypertensive medication, diabetes, history of myocardial infarction and heart failure. False discovery rate (FDR) was used to adjust for multiple testing. Eicosanoids with FDR < 0.05 were considered significant. In total, 2676 AF-free individuals (mean age 66 ± 9 years, 56% females) were followed for mean 10.8 ± 3.4 years; 351 participants developed incident AF. Six eicosanoids were associated with incident AF after adjusting for multiple testing (FDR < 0.05). A joint score was built from the top eicosanoids weighted by their effect sizes, which was associated with incident AF (HR = 2.72, CI = 1.71-4.31, P = 2.1 × 10
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
The association between eicosanoids and incident atrial fibrillation in the Framingham Heart Study. · full record | OpenQuestion